- ICH GCP
- EU 임상 시험 레지스트리
최신 시험
EudraCT Number: 2012-005496-14 | Sponsor Protocol Number: MRZ60201_3072_1 | Start Date: | |||||||||||
Sponsor Name: Merz Pharmaceuticals GmbH | |||||||||||||
Full Title: Prospective, multicenter, randomized, double-blind, parallel-group, dose-response study of three doses Xeomin® (incobotulinumtoxinA, NT 201) for the treatment of upper limb spasticity alone or comb... | |||||||||||||
Medical condition: Upper limb spasticity or combined upper and lower limb spasticity in children and adolescents (age 2 - 17 years) with cerebral palsy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003093-21 | Sponsor Protocol Number: 20091977 | Start Date: | ||||||
Sponsor Name: Medical Department I | ||||||||
Full Title: Influence of combined therapy of niacin and statins on stem cell mobilization and inflammatory parameters in patients suffering from coronary artery disease – randomized clinical study - | ||||||||
Medical condition: Have stable coronary artery disease (i.e. no acute event like myocardial infarction or PTCA less then 3 months ago) | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: DE (Completed) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002223-32 | Sponsor Protocol Number: E2007-0507 | Start Date: | ||||||
Sponsor Name: Charité Universitaetsmedizin | ||||||||
Full Title: A multicentre, double-blind, randomised placebo-controlled trial of sodium bicarbonate to prevent acute kidney injury in patients undergoing cardiopulmonary bypass surgery. | ||||||||
Medical condition: Cardiac surgical patients in whom the use of cardiopulmonary bypass is planned and having at least one ore more of the following risk factors for post-operative acute kidney injury • Age ≥ 70 years... | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: DE (Completed) IE (Prematurely Ended) | ||||||||
Trial results: View results |
EudraCT Number: 2014-001740-38 | Sponsor Protocol Number: P130910 | Start Date: | |||||||||||
Sponsor Name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004708-32 | Sponsor Protocol Number: 232SM302 | Start Date: | |||||||||||
Sponsor Name: Biogen Idec Research Limited | |||||||||||||
Full Title: A Long-Term Extension Study of Nusinersen (BIIB058) Administered at Higher Doses in Participants With Spinal Muscular Atrophy Who Previously Participated in an Investigational Study With Nusinersen | |||||||||||||
Medical condition: Muscular Atrophy, Spinal | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) ES (Ongoing) HU (Ongoing) DE (Ongoing) PL (Completed) IT (Ongoing) NL (Ongoing) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003346-27 | Sponsor Protocol Number: ATYR1940-C-003 | Start Date: | |||||||||||
Sponsor Name: ATYR PHARMA, INC. | |||||||||||||
Full Title: An Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Fa... | |||||||||||||
Medical condition: Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011095-30 | Sponsor Protocol Number: Primo2009 | Start Date: | |||||||||||||||||||||
Sponsor Name: Medizinische Fakultät Mannheim, Ruprecht-Karls-Universität Heidelberg | |||||||||||||||||||||||
Full Title: Intra-individual comparison of Gd-EOB-DTPA disodium (Primovist) and Gadobutrol (Gadovist) in patients with suspicion of hepatocellular carcinoma | |||||||||||||||||||||||
Medical condition: Patients of both genders are eligible for this study in case they present with suspicion of HCC after Gadovist® -enhanced MRI. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000989-35 | Sponsor Protocol Number: P101001 | Start Date: | |||||||||||
Sponsor Name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000346-36 | Sponsor Protocol Number: BPLG-004 | Start Date: | |||||||||||
Sponsor Name: BioPartners GmbH [...] 1. BioPartners GmbH 2. LG Life Science Ltd. | |||||||||||||
Full Title: A Phase III, Multi-centre, Randomised, Parallel Group Study of Safety and Efficacy of the LB03002 a New Sustained Release Formulation of Human Recombinant Growth Hormone as Compared to Standard Dai... | |||||||||||||
Medical condition: pre-pubertal drug naïve growth-deficient children with insufficient endogenous growth hormone secretion | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) FI (Prematurely Ended) SE (Prematurely Ended) SK (Completed) HU (Completed) CZ (Prematurely Ended) IT (Completed) DE (Completed) LT (Prematurely Ended) EE (Prematurely Ended) LV (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-004093-40 | Sponsor Protocol Number: 08-PIR-03 | Start Date: | ||||||||||||||||
Sponsor Name: Nektar Therapeutics | ||||||||||||||||||
Full Title: A Multicenter, Open-Label, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of NKTR-102 (PEG-Irinotecan) Versus Irinotecan in Patients with Second-Line, Irinotecan-Naïve, KRAS-Mutant, ... | ||||||||||||||||||
Medical condition: Refractory Solid Tumors (Colorectal Cancer) Tumores sólidos refractarios (Cáncer colorrectal) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) BE (Prematurely Ended) DE (Completed) GB (Completed) SK (Completed) LV (Completed) | ||||||||||||||||||
Trial results: View results |